Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Neutropenia is a common complication from dalpiciclib. Mecapegfilgramtim (code name
HHPG-19K), a long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF),
has been developed. The study aim to evaluate the safety and efficiency of mecapegfilgrastim
for prophylaxis of dalpiciclib -induced neutropenia in patients with advanced HR+/HER2-
breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University